文献速递核素与放射性配体治疗神经核医学肿瘤 PET/CT

[177Lu]Lu-DOTATATE治疗难治性脑膜瘤:法国多中心MELUTE队列结果

Radiopharmaceutical Therapy with [177Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort.
PubMed 文献 · J Nucl Med · 2026-10-15

6个月无进展生存率为70%,中位无进展生存期14.6个月,中位总生存期27.6个月,3级不良事件发生率16%、主要为淋巴细胞减少。

要点

  • 6个月无进展生存率70%(95%CI 58.7-80.4%),中位无进展生存期14.6个月。
  • 中位总生存期27.6个月,3级不良事件16%,主要为淋巴细胞减少。
  • 脑膜瘤WHO分级独立预测无进展生存,基线肿瘤生长速度高和既往系统治疗与更差总生存相关。

核心结论

  • MELUTE研究显示[177Lu]Lu-DOTATATE在治疗选择有限的难治性脑膜瘤中具有令人鼓舞的疗效和良好的安全性。

研究设计与样本

  • 治疗方案为7.4 GBq每8周、最多4周期,基线及治疗后[68Ga]Ga-DOTATOC PET和脑MRI由中心统一审阅。
  • 主要终点为采用神经肿瘤学疗效评估 volumetric 标准的6个月无进展生存率,次要终点为无进展生存期、总生存期和安全性。

主要发现

  • 6个月无进展生存率为70%(95%CI 58.7-80.4%),中位无进展生存期14.6个月(95%CI 13.3-18.5个月)。
  • 中位总生存期为27.6个月(95%CI 24.2个月至未达到)。
  • 脑膜瘤WHO分级独立预测无进展生存,较高的Karnofsky体能状态和皮质类固醇使用为保护因素。
  • 更差的总生存与较高的基线肿瘤生长速度和既往系统治疗相关。

关键数值与推荐

  • 治疗方案为[177Lu]Lu-DOTATATE 7.4 GBq每8周、最多4周期。
  • 6个月无进展生存率70%(95%CI 58.7-80.4%),中位无进展生存期14.6个月(95%CI 13.3-18.5个月)。
  • 中位总生存期27.6个月(95%CI 24.2个月至未达到)。
  • 3级不良事件发生率16%,主要为淋巴细胞减少。

临床怎么用

  • 对于治疗选择有限的难治性脑膜瘤患者,[177Lu]Lu-DOTATATE可作为多学科评估后的 compassionate-use 选择。
  • 治疗前应评估WHO分级、Karnofsky体能状态、基线肿瘤生长速度及既往系统治疗史以辅助风险分层。
  • 治疗期间需监测淋巴细胞减少等血液学毒性。

局限性

  • 本研究为回顾性多中心队列研究,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence supporting the efficacy and safety of [177Lu]Lu-DOTATATE in refractory meningiomas derives mainly from small, single-center studies. The French national multicenter MELUTE study aimed to consolidate these data using a standardized regimen within a compassionate-use program approved by a national multidisciplinary tumor board. Methods: In this retrospective multicenter cohort study, patients with refractory meningiomas treated with [177Lu]Lu-DOTATATE in 18 French centers between July 2022 and December 2024 were included. Treatment consisted of 7.4 GBq every 8 wk for up to 4 cycles. Clinical data (demographics, histologic World Health Organization grade [WHO], prior treatments, number of cycles, toxicity, progression, survival status as of October 1, 2025) were collected. Baseline [68Ga]Ga-DOTATOC PET and brain MRI scans obtained before and after treatment were centrally reviewed. The primary endpoint was 6-mo progression-free survival (PFS) assessed using volumetric Response Assessment in Neuro-Oncology Group criteria. Secondary endpoints were PFS, overall survival (OS), and safety. Results: Sixty-nine patients were included (mean age, 65.1 ± 13.2 y; 52% female): 13 WHO grade 1, 42 WHO grade 2, 8 WHO grade 3, and 6 without histology. Most had prior surgery (86%) or radiotherapy (93%); 32% received prior systemic therapy. Twelve patients (17%) did not complete 4 cycles; only one discontinuation was toxicity-related. Six-month PFS was 70% (95% CI, 58.7-80.4%). Median PFS was 14.6 mo (95% CI, 13.3-18.5 mo), and median OS was 27.6 mo (95% CI, 24.2 mo to not reached). Grade 3 adverse events, mainly lymphopenia, occurred in 16%. Meningioma WHO grade independently predicted PFS, whereas higher Karnofsky performance status and corticosteroid use were protective; worse OS was associated with higher baseline tumor growth rate and prior systemic therapy. Conclusion: MELUTE demonstrates promising efficacy and favorable safety of [177Lu]Lu-DOTATATE in refractory meningiomas with limited therapeutic options.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Garabedian N, Zaragori T, Tabouret E, et al. Radiopharmaceutical Therapy with [177Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort. J Nucl Med. 2026. PMID: 42880958. doi:10.2967/jnumed.126.272735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。